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Preeclampsia is divided into early-onset (delivery before 34 weeks of gestation) and late-
onset (delivery at or after 34 weeks) subtypes, which may rise from different etiopathogenic
backgrounds. Early-onset disease is associated with placental dysfunction. Late-onset dis-
ease develops predominantly due to metabolic disturbances, obesity, diabetes, lipid dys-
function, and inflammation, which affect endothelial function. Our aim was to use cluster
analysis to investigate clinical factors predicting the onset and severity of preeclampsia in a
cohort of women with known clinical risk factors.
Methods
We recruited 903 pregnant women with risk factors for preeclampsia at gestational weeks
12+0–13+6. Each individual outcome diagnosis was independently verified from medical rec-
ords. We applied a Bayesian clustering algorithm to classify the study participants to clus-
ters based on their particular risk factor combination. For each cluster, we computed the risk
ratio of each disease outcome, relative to the risk in the general population.
Results
The risk of preeclampsia increased exponentially with respect to the number of risk factors.
Our analysis revealed 25 number of clusters. Preeclampsia in a previous pregnancy
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(n = 138) increased the risk of preeclampsia 8.1 fold (95% confidence interval (CI) 5.7–11.2)
compared to a general population of pregnant women. Having a small for gestational age
infant (n = 57) in a previous pregnancy increased the risk of early-onset preeclampsia 17.5
fold (95%CI 2.1–60.5). Cluster of those two risk factors together (n = 21) increased the risk
of severe preeclampsia to 23.8-fold (95%CI 5.1–60.6), intermediate onset (delivery between
34+0–36+6 weeks of gestation) to 25.1-fold (95%CI 3.1–79.9) and preterm preeclampsia
(delivery before 37+0 weeks of gestation) to 16.4-fold (95%CI 2.0–52.4). Body mass index
over 30 kg/m2 (n = 228) as a sole risk factor increased the risk of preeclampsia to 2.1-fold
(95%CI 1.1–3.6). Together with preeclampsia in an earlier pregnancy the risk increased to
11.4 (95%CI 4.5–20.9). Chronic hypertension (n = 60) increased the risk of preeclampsia
5.3-fold (95%CI 2.4–9.8), of severe preeclampsia 22.2-fold (95%CI 9.9–41.0), and risk of
early-onset preeclampsia 16.7-fold (95%CI 2.0–57.6). If a woman had chronic hypertension
combined with obesity, gestational diabetes and earlier preeclampsia, the risk of term pre-
eclampsia increased 4.8-fold (95%CI 0.1–21.7). Women with type 1 diabetes mellitus had a
high risk of all subgroups of preeclampsia.
Conclusion
The risk of preeclampsia increases exponentially with respect to the number of risk factors.
Early-onset preeclampsia and severe preeclampsia have different risk profile from term
preeclampsia.
Introduction
Preeclampsia affects 3%[1] of all pregnancies. It is a systemic disease with a multifactorial
background. Preeclampsia is diagnosed when a pregnant woman develops hypertension and
proteinuria after 20 weeks of gestation. Recent recommendation by the American College of
Obstetricians and Gynecologists [2] further proposes that in the absence of proteinuria, pre-
eclampsia could be diagnosed when newly diagnosed hypertension occurs in association with
thrombocytopenia, impaired liver function, new development of renal insufficiency, pulmo-
nary edema, or new-onset cerebral or visual disturbances.
Preeclampsia can be life-threatening both to the mother and the unborn child. Due to its
multifactorial etiology, the outcome and progression of preeclampsia is challenging to predict.
The role of the placenta is important in the pathogenesis, and the clinical findings are a conse-
quence of endothelial dysfunction [3]. The disease can be roughly divided into early-onset and
late-onset subtypes which evidently rise from different etiopathogenic backgrounds [4]. Early-
onset disease is associated with placental dysfunction. It is often accompanied by intrauterine
growth restriction, the risk runs in families and women with history of early-onset preeclamp-
sia have an increased risk of cardiovascular disease later in life [5]. Late-onset preeclampsia
develops due to metabolic disturbances, obesity, diabetes, lipid dysfunction, and inflammation
[6] all of which affect endothelial function. Placental hypoplasia and vascular lesions frequently
present in early-onset disease are often absent in the late-onset disease [7].
Using vasoactive markers, placental growth factor (PlGF) and soluble vasoactive endothelial
growth factor reseptor-1 (s-Flt1), preeclampsia can be divided into angiogenic and non-angio-
genetic subgroups [8]. Early-onset and severe preeclampsia seem to form predominantly the
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angiogenetic subtype and non-angiogenic subtype has milder and later course of the disease
[9].
Recently encouraging progress has been achieved in the field of preeclampsia prevention
[10]. Meta-analyses show that low-dose aspirin initiated in the early precnancy in high-risk
women may prevent early and severe preeclampsia or at least delay the onset of the disease
[11,12]. However, preeclampsia is a heterogenic disorder. There are great challenges in pre-
dicting who will eventually develop severe or early-onset disease and, accordingly, benefit
most from the use of aspirin.
The present study explores the features of this high-risk cohort.
The aim was to explore predicting factors affecting the onset and severity of preeclampsia.
We used cluster analysis in a prospectively collected cohort of women with known clinical risk
factors for preeclampsia. We will discuss the findings in the context of current recommenda-
tions for initiating aspirin to prevent preeclampsia in high-risk women.
Methods
The Predo Project
The study cohort consists of women recruited in the multidisciplinary Prediction and Preven-
tion of Preeclampsia and Intrauterine Growth Restriction (PREDO) Project between Septem-
ber 2005 and December 2009 [13,14]. The project has three arms: obstetric [15](including an
aspirin trial [13]), genetic [16], and psychological [17]. We recruited 972 pregnant women
with risk factors for preeclampsia and 110 randomly selected pregnant women without known
risk factors as a comparison group at 12+0 to 13+6 weeks and days of gestation. The recruitment
took place when the women attended the first ultrasound screening in one of the ten hospital
maternity clinics participating in the PREDO Project; Women´s Hospital, Ka¨tilo¨opisto Mater-
nity hospital and Jorvi Hospital at Helsinki University Central Hospital, Hyvinka¨a¨ Hospital,
Kanta-Ha¨me Central Hospital, Pa¨ija¨t-Ha¨me Central Hospital, Tampere University Hospital,
Kuopio University Hospital, Northern Karelia Central Hospital, and Iisalmi Hospital. The
study protocol has been approved by the Ethics Committee of the Helsinki and Uusimaa Hos-
pital District and by the participating hospitals. A written informed consent was obtained
from all participants.
Inclusion criteria and definitions. The inclusion and exclusion criteria for the PREDO
Project are presented in Table 1. Women with one or more of the risk factors for preeclampsia
Table 1. Number of women included in the cluster analysis with each risk factor. A participant may
have one or more risk factors.
Risk factor N %
Pre-eclampsia in a previous pregnancy 222 4.6%
Small for gestational age infant in a previous pregnancy 106 11.7%
Chronic hypertension 136 15.1%
Gestational diabetes, diet-treated 90 10%
Gestational diabetes, insulin treated 12 1.3%
Body mass index over 30 kg/m2 353 39.1%
Age under 20 years 27 3%
Age over 40 years 149 16.5%
Systemic lupus erythematosus 4 0.4%
Sjo¨gren’s syndrome 13 1.4%
Type 1 diabetes 18 2.0%
Previous fetal demise 37 4.1%
https://doi.org/10.1371/journal.pone.0174399.t001
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were invited to participate in the order of arrival unless any of the exclusion criteria were pres-
ent. We performed uterine artery blood flow measurements by Doppler ultrasound for all par-
ticipants at 12+0 to 13+6 weeks of gestation. Women who had bilateral second-degree notch
were allocated to the medication group. These women (n = 152) were randomized to receive
aspirin in low dose (100 mg/day) or placebo until 35+0 weeks of gestation, or delivery. Women
with risk factors but no aforementioned ultrasound finding were allocated in the follow-up
groups. We also recruited 110 women without known risk factors as a control group. All study
participants filled a questionnaire concerning their health. Pregnancy data were collected from
the medical records of maternity clinics and hospitals.
Participants in the cluster analysis
Participants with risk factors for preeclampsia, 903 women, were included in this cluster analy-
sis. Women who were randomized to receive the low-dose aspirin (n = 69) [13]were excluded.
The clinical characteristics of the study groups are presented in Table 2.
Outcomes
Primary outcomes in the study were preeclampsia (blood pressure 140/90 mmHg in two
consecutive measurements and proteinuria 0.3 g/24hours) [18], gestational hypertension
(new onset hypertension after 20 weeks of gestation, without proteinuria), and birth weight
standard deviation (SD) score as a continuous variable calculated according to Finnish stan-
dards [19].
Secondary outcomes were early-onset preeclampsia (delivery before 34+0 weeks of gesta-
tion), late-onset preeclampsia (delivery at or after 34+0 weeks of gestation), preterm pre-
eclampsia (delivery before 37+0 weeks of gestation), term preeclampsia (delivery at or after
37+0 weeks of gestation), intermediate preeclampsia (delivery between 34+0–36+6 weeks of ges-
tation), severe preeclampsia (blood pressure160 mmHg systolic and/or110 mmHg dia-
stolic and/or proteinuria 5 g/24hours), small for gestational age (SGA) (birthweight
<-2SD), gestational diabetes (diet or insulin treated), chronic hypertension (140/90 mmHg
or medication for hypertension before 20 weeks of gestation), HELLP syndrome (hemolysis,
elevated liver enzymes, low platelets) and fetal demise (fetal death after 22th gestational week
or over 500g weight).
Each individual outcome diagnosis was set by a jury, which consisted of two physicians and
a study nurse. They met face-to-face and reviewed the hospital and maternity clinic records of
each participant.
Methods of the cluster analysis
We applied a Bayesian clustering algorithm based on mixtures of binary variables, see, e.g.
[20], using an implementation available in the Bayesian Analysis of Population Structure
(BAPS) software [21] to classify the study participants on the basis of their risk factors. The
algorithm detected 25 clusters, corresponding to different risk factor combinations. For each
cluster detected, we computed the risk ratio of each disease outcome, relative to the risk in the
general population. The significance and confidence intervals of the risks in the different clus-
ters were computed using the exact binomial test (function binom.test in the R software). The
false discovery rates (FDR) were computed using function p.adjust in R.
The risk of preeclampsia and its subtypes in the general Finnish population for these out-
comes were estimated according to data from the National Institute for Health and Welfare
registers from the year 2013; Medical Birth Register and Care Register for Health Care; pre-
eclampsia 2.5% (from these 24% severe, 8% early-onset, 15% intermediate, 77% term, 23%
Cluster analysis to estimate the risk of preeclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0174399 March 28, 2017 4 / 14
preterm) with frequences obtained by request from the register authorities and gestational
hypertension 4.4%, small for gestational age (SGA) 2.3%, gestational diabetes 9%.
Results
Of the 903 women 86 (9.5%) developed preeclampsia. Of those with preeclampsia 10 (11.6%)
had early-onset disease and 36 (41.9%) severe disease. 465 women (51.5%) did not meet any of
the primary or secondary outcome criteria whereas 438 (48.5%) had one or more of these preg-
nancy complications (Table 3).
In the control group of 110 women without risk factors two developed preeclampsia; one of
them had severe and the other non-severe late-onset preeclampsia. Eighty-seven percent of
women in the healthy control group did not meet any of our primary or secondary outcome
criteria.
Systemic lupus erythematosus was inclusion criterion for four women and Sjo¨gren’s syn-
drome for 13 women. None developed preeclampsia.
Table 2. Baseline and pregnancy characteristics.
Characteristics Mean
(SD)
Controls with no risk
factors for preeclampsia
n = 110
One or more risk factors,




preeclampsia n = 36
Late nonsevere
preeclampsia n = 50
Age, years 30.0 (4.3)* 32.6 (6.0)* 31.6 (5.4) 32.5 (5.3) 31.0 (5.4)
Weight before
pregnancy, kg
62.9 (8.3)*˚ 76.6 (18.4)* 79.2 (19.7)˚ 77.6(19.1) 80.4 (20.2)
Weight in the end of
pregnancy, kg
77.6 (10.0)*˚ 89.7(17.9)* 93.1 (19.6)˚ 91.7 (19.7) 94.0 (19.7)
BMI before pregnancy,
kg/m2
22.6 (2.7) 27.8 (6.5) 28.6 (6.7) 28.6(7.1) 28.9 (6.8)
BMI at the end of
pregnancy, kg/m2
27.8 (2.9) 32.5 (6.3) 33.6 (6.9) 33.9 (7.7) 33.8 (6.5)
BMI change, kg/m2 5.3 (1.6) 4.6 (2.1) 4.9 (1.8) 4.8(2.1) 4.9(1.9)
Nulliparous 60% *˚ 31% * 31%(1.0)˚ 42% 22.%
Blood pressure systolic
highest, mmHg
126.2 (13.1) 135.6 (17.0) 169.2 (19.7) 182.3(17.0)# 159.9 (15.0)#
Blood pressure diastolic
highest, mmHg
81.2 (7.8) 88.4 (11.6) 105.0 (10.1) 110.2 (9.8)# 101.3 (8.7)#
Proteinuria highest, g/
24 hour
- - 2.3 (3.0) 3.6 (4.1)# 1.3 (1.2)#
Gestational age, weeks 40.1 (1.4)* 39.8 (1.6)€ 37.6 (3.3)*€ 35.7 (3.9)# 39.0 (1.7)#
Birthweight, g 3463 (411)* 3578(550) 3058 (932)* 2420 (921)# 3519 (621)#
Relative birthweight, SD -0.2 (0.8) 0.05 (1.1)€ -0.5 (1.4)€ -1.2 (1.0)# 0.1 (1.4)#
Placental weight, g 584 (108)* 619 (133)*€ 560 (170)€ 464(146)# 626 (155)#
Uterine artery pulsatility
index mean
1.45 (0.38)* 1.51 (0.44)€ 1.68 (0.47)*€ 1.74 (0.45) 1.64(0.52)
Mother’s birthweight, g 3513 (488) 3406 (522) 3338 (636) 3410 (598) 3298 (656)
Differences between subjects were calculated by independent-sample t-test for continuous variables and chi-square test for categorical values. BMI = body
mass index, relative birthweight = birthweight normalized for gestational age and gender of the newborn. Symbols for statistically significant difference
(P<0.05):
* between controls without risk factors and risk women without preeclampsia,
˚ between controls without risk factors and women with preeclampsia,
€ between risk women without preeclampsia and women with preeclampsia,
# between early/severe preeclampsia and late nonsevere preeclampsia,
https://doi.org/10.1371/journal.pone.0174399.t002
Cluster analysis to estimate the risk of preeclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0174399 March 28, 2017 5 / 14
Women with preeclampsia had significantly more often induced labour or caesarean sec-
tions, and their new-borns had lower Apgar scores (Table 4).
Results of the cluster analyses
Heat map of risk relative to general population. The heat map (Fig 1) shows the risk of
developing preeclampsia in the high-risk group including severe, early-onset, term, preterm
and intermediate preeclampsia as compared to the risk of developing the same outcome in a
general population of pregnant women. The risk ratios of the 19 most frequent clusters are
presented in Table 5. The risk ratio table including all clusters is presented in the supplement
material in S1 Table.
The coloured cells in the heatmap signal significant outcomes according to nominal
p<0.05 level. After accounting for the number of tests the results correspond to false discovery
rate FDR = 0.14 considered appropriate in this exploratory analysis. A similar figure, where
significance was determined using the Bonferroni correction over the 25 clusters times 10 out-
comes (250 conditions), is shown as Supplementary S1 Fig. Women with preeclampsia in a
Table 3. Confirmed diagnoses in the cohort of high-risk women.
Diagnoses n %
All preeclampsia 86 9.5
Term preeclampsia 59 6.5
Preterm preeclampsia 27 3.0
Early preeclampsia 10 1.1
Severe preeclampsia 35 3.9
Gestational hypertension 96 10.6
Chronic hypertension 179 19.5
Gestational diabetes, diet-treated 171 18.9
Gestational diabetes, insulin-treated 42 4.7
HELLP syndrome* 6 0.7
Eclampsia 1 0.1
Small for gestational age 34 3.8
Fetal demise 2 0.2
Normal pregnancy 465 51.4
* HELLP = hemolysis, elevated liver enzymes and low platelet count
https://doi.org/10.1371/journal.pone.0174399.t003
Table 4. Delivery characteristics.
Controls with no risk factors for preeclampsia High risk women, no preeclampsia Preeclampsia p
Induced delivery 13 (11.8%) 230 (28.4%) 57 (67.1%) <0.0001
Cesarean section 15 (13.7%) 185 (22.7%) 35 (40.7%) <0.0001
Apgar 1min 8.8 (0.9)* 8.6 (1.3)˚ 8.0 (1.8)*˚ <0.001
Apgar 5 min 9.4 (0.6)* 9.1 (1.0)˚ 8.5 (1.4)*˚ <0.001
Apgar 10 min 9.9 (0.5)*# 9.4 (0.8)#˚ 9.0 (0.9)*˚ <0.05
Umbilical artery pH 7.2 (0.1) 7.3 (0.1) 7.2 (0.1) ns
*statistically significant difference between controls with no risk factors and women with pre-eclampsia,
˚ statistically significant difference between high risk women without preeclampsia and women with pre-eclampsia,
# statistically significant difference between controls with no risk factors and high risk women without preeclampsia tested by Anova with Bonferroni
corrections for continuous variables and Pearson’s chi square test for categorical variables
https://doi.org/10.1371/journal.pone.0174399.t004
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previous pregnancy, chronic hypertension, a small for gestational age new-born, or type 1 dia-
betes mellitus were at high risk of early-onset, severe, preterm and intermediate preeclampsia.
Preeclampsia in a previous pregnancy and obesity (body mass index (BMI) over 30 kg/m2)
were the most important single risk factors for term preeclampsia. Obese women had
increased risk of any (OR 2.1, 95%CI 1.1–3.6), term (OR 2.3, 95%CI 1.1–4.2) and severe (5.2,
95%CI 2.1–10.5) preeclampsia. No association with preterm or early-onset preeclampsia was
observed. Obesity combined with other risk factors, chronic hypertension, and type 1 diabetes
mellitus further increased the risk of preeclampsia. Type 1 diabetes mellitus without other risk
factors increased the risk of preterm, but not term preeclampsia. Age over 40 years or under 20
years in a healthy woman without other risk factors did not increase the risk of preeclampsia
in our cohort.
The risk of preeclampsia increased exponentially (linearly on the logarithmic scale) with
increase to the number of risk factors (Fig 2). In Table 6 we present some clusters as an
example.
Fig 1. Heat map—Results of the cluster analysis. The heatmap presents the risk factors (columns) in the
different clusters on the left side with black boxes. The rows correspond to the 25 clusters (C1-C25) identified
on the basis of the risk factor profiles, and the sizes of the clusters are shown on the left side of the heat map
(n = 226 etc.). The size (i.e. area) of the black box illustrates the proportion of women in the particular cluster
with the risk factor in question. Right side of the heatmap presents the risk ratios of the outcomes. The colour
of the cell represents the estimated risk ratio of the corresponding outcome in the corresponding cluster, and
the colour encoding is shown on the right side of the heatmap. Those cells are colored which are significant at
the nominal 5% level (see text for discussion). The exact risk ratios are presented in Table 5.
https://doi.org/10.1371/journal.pone.0174399.g001
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Discussion
In this study the risk of preeclampsia increased exponentially as the number of risk factors
increased. Women who developed preterm or severe preeclampsia had a different risk profile
than those who developed term preeclampsia. Previous preeclampsia, chronic hypertension,
and type 1 diabetes mellitus were strong risk factors for severe and preterm preeclampsia in
our cohort. SGA newborn in an earlier pregnancy was a strong risk factor for early-onset pre-
eclampsia. Obesity increased the risk of term preeclampsia and severe preeclampsia. Neither
age below 20 years nor age over 40 years, gestational diabetes or fetal demise as a sole risk fac-
tors predicted increased risk.
Within this research frame the incidence of preeclampsia in a general population is of par-
ticular importance. Incidence of preeclampsia in literature is estimated as 3% [1]. For this
work we wanted to determine incidence, which would be accurate in the Finnish population.
Table 5. Risk ratios and 95% Confidence Intervals (CIs) of the cluster analysis. The marking C1 etc. is referring to certain row in the heatmap. If the risk
factor is inside brackets, only a portion of women in the cluster had that risk factor.
End diagnosis, RR (95%CI)












BMI over 30 kg/m (C1) 2.1 (1.1, 3.6) 5.2 (2.1, 10.5) 2.2 (0.1, 12.2) 2.3 (1.1, 4.2) 1.2 (0.02, 6.4) 1.5 (0.2, 5.4)
Pre-eclampsia (C2) 8.1 (5.6, 11.2) 7.2 (2.7, 15.4) 7.2 (0.9, 25.7) 9.2 (6.0, 13.0) 5.7 (1.2, 16.4) 5.0 (1.4, 12.5)
Age over 40 years (C3) 0.4 (0.01, 2.1) 0.0 (0.0, 5.9) 0.0 (0.0, 17.8) 0.5 (0.0, 2.8) 0.0 (0.0, 9.3) 0.0 (0.0, 6.1)
Chronic hypertension (C4) 5.3 (2.4, 9.8) 22.2 (9.9, 41.0) 16.7 (2.0, 57.6) 2.6 (0.5, 7.3) 13.2 (2.7, 36.6) 14.4 (4.8, 31.7)
Small fo gestational age (age
>40) (C5)
1.4 (0.2, 4.8) 5.8 (0.7, 20.2) 17.5 (2.1, 60.5) 0.0 (0.0, 3.3) 0.0 (0.0, 16.5) 6.1 (0.7, 20.9)
Gestational diabetes mellitus
(sga, ch) (C6)
1.1 (0.03, 5.8) 0.0 (0.0, 16.2) 0.0 (0.0, 48.7) 1.5 (0.04, 7.6) 0.0 (0.0, 25.6) 0.0 (0.0, 16.8)
Chronic hypertension and BMI
over 30 (C7)
5.2 (1.5, 11.9) 5.4 (0.1, 27.8) 0.0 (0.0, 56.1) 5.1 (1.1, 13.6) 8.5 (0.2, 44.0) 5.6 (0.1, 28.8)
Age under 20 (bmi) (C8) 2.8 (0.3, 9.1) 5.7 (0.1, 29.6) 17.2 (0.4, 88.8) 1.8 (0.1, 9.4) 0.0 (0.0, 31.4) 5.9 (0.2, 30.6)
Fetus mortus (pe,sga, ch) (C9) 3.1 (0.4, 10.1) 6.4 (0.2, 32.7) 0.0 (0.0, 66.1) 4.0 (0.5, 13.2) 0.0 (0.0, 34.8) 0.0 (0.0, 22.8)
GDM and BMI over 30 (CH)
(C10)
0.0 (0.0, 5.7) 0.0 (0.0, 23.7) 0.0 (0.0, 71.2) 0.0 (0.0, 7.5) 0.0 (0.0, 37.5) 0.0 (0.0, 24.6)
Pre-eclampsia and sga (bmi)
(C11)
7.6 (2.2, 16.8) 23.8 (5.1, 60.6) 0.0 (0.0, 80.5) 5.0 (0.6, 16.0) 25.1 (3.1, 79.9) 16.4 (2.0, 52.4)
Pre-eclampsia and BMI>30
(C12)
11.4 (4.5, 20.9) 0.0 (0.0, 26.9) 0.0 (0.0, 80.5) 10.0 (2.9, 22.1) 25.1 (3.1, 79.9) 16.4 (2.0, 52.4)
Diabetes mellitus type1 (C13) 11.8 (4.1, 22.4) 19.6 (2.4, 60.7) 58.8 (7.3, 182.2) 3.1 (0.1, 15.1) 31.0 (3.8, 95.9) 40.6 (11.7, 86.0)
Sjo¨gren’s syndrome (C14) 0.0 (0.0, 9.9) 0.0 (0.0, 41.2) 0.0 (0.0, 123.5) 0.0 (0.0, 13.0) 0.0 (0.0, 65.0) 0.0 (0.0, 42.6)
BMI and age >40 (C15) 3.1 (0.1, 14.4) 12.8 (0.3, 60.1) 0.0 (0.0, 123.5) 0.0 (0.0, 13.0) 20.2 (0.5, 94.8) 13.3 (0.3, 62.1)
GDM and age >40 (C16) 0.0 (0.0, 10.6) 0.0 (0.0, 44.1) 0.0 (0.0, 132.3) 0.0 (0.0, 13.9) 0.0 (0.0, 69.6) 0.0 (0.0, 45.6)
Pre-eclampsia, GDM(diet),
BMI>30 (C17)
10.0 (2.2, 22.9) 0.0 (0.0, 44.1) 0.0 (0.0, 132.3) 8.8 (1.1, 25.5) 21.9 (0.6, 101.3) 14.4 (0.4, 66.3)
Pre-eclampsia, CH, BMI>30
(C18)
7.3 (0.9, 20.7) 15.2 (0.4, 68.8) 0.0 (0.0, 142.5) 4.8 (0.1, 21.7) 23.9 (0.6, 108.6) 15.7 (0.4, 71.2)
GDM insulin treated (pe, ch,
bmi)(C19)
7.3 (0.9, 20.7) 0.0 (0.0, 47.5) 0.0 (0.0, 142.5) 9.6 (1.2, 27.3) 0.0 (0.0, 75.0) 0.0 (0.0, 49.1)
Severe pre-eclampsia = blood pressure160 mmHg systolic and/or110 mmHg diastolic and/or proteinuria 5 g/24hours, early pre-eclampsia = delivery
before 34+0 weeks of gestation, term pre-eclampsia = delivery at or after 37+0 weeks of gestation, intermediate pre-eclampsia = delivery between 34+0–36
+6 weeks of gestation, preterm pre-eclampsia = delivery before 37+0 weeks of gestation. BMI >30, SGA = small for gestational age (birthweight < 2SD),
CH = chronic hypertension, PE = preeclampsia, GDMd = gestational diabetes, diet treated.
https://doi.org/10.1371/journal.pone.0174399.t005
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According to combined data, from the National Medical Birth Registry and Care Register
(National Institute for Health and Welfare) 2.5% of babies were born from preeclamptic preg-
nancies in 2013. Similar rates have been reported in other Nordic countries: according to the
Danish hospital discharge registry 2.72% of women who gave birth in Northern Sealand in
years 1998–2000 had preeclampsia [22]. In the medical birth registry data of Norway, covering
Fig 2. Risk ratio grows exponentially (linearly on the logarithmic scale) as the number of risk factors
increases. The increase is significant when the risk of preeclampsia is predicted by the number of risk factors
using logistic regression (Preeclampsia (total)(n = 86), p = 0.0181, b = 0.3429)
https://doi.org/10.1371/journal.pone.0174399.g002
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1 million births in years 1986–2005, preeclampsia rate was 3.7% [23]. While no validation
studies exist for preeclampsia diagnoses in the Finnish healthcare registers, studies of the Nor-
wegian [24] and Danish [22] registries have been validated against medical records according
to criteria similar to those used in the present study. The prevalence of preeclampsia in the
study populations was relatively similar whether obtained from registry or whether based on
medical records: 4.4% and 3.8%, respectively, in the Norwegian Study and 2.7% and 2.9% in
the Danish study. While some individuals are misclassified according to registry diagnoses, as
indicated by the 99% specificity and 69% [22] and 43% [22] sensitivity, the similar prevalences
indicate that the registry estimate of prevalence used here as reference is adequately accurate.
The strength of our study is the prospectively recruited, well-characterised cohort of
women with increased risk of preeclampsia. However, we had limited information of the onset
and severity of preeclampsia in the earlier pregnancies of our participants, and whether pre-
eclampsia had occurred in one or more previous pregnancies. Therefore the effect of those risk
factors is impossible to evaluate. According to earlier studies, women with a history of early-
onset preeclampsia have higher risk of recurrent preeclampsia than women with late-onset dis-
ease [25,26]. Moreover, women with previous preterm preeclampsia have increased risk of
adverse pregnancy outcome in their second pregnancy even in the absence of preeclampsia
[27].
In this study a history of preeclampsia was a strong risk factor for recurrent preeclampsia.
Duckitt and Harrington reported a seven-fold increase in incidence of preeclampsia in women
who had preeclampsia in an earlier pregnancy compared to women without such a history
[25]. In our cohort, history of giving birth to a SGA new-born in a previous pregnancy seemed
to increase the risk of early-onset, preterm and severe preeclampsia in subsequent pregnancies.
Conversely, having a preterm preeclampsia in an earlier pregnancy has shown to be associated
with risk of giving birth to a SGA newborn in a later non preeclamptic pregnancy [28]. This
reflects the common placenta derived pathogenesis of these pregnancy outcomes. Preeclamp-
sia and SGA are different entities of the same placental disease. Ness and Sibai [29] hypothe-
sized that shallow placentation is preceded by endothelial dysfunction in both preeclamptic
Table 6. Important risk factors and clusters and number of women who developed preeclampsia in each group.
Risk factors Number of women with the risk factor
(s)
Number of women who developed preeclampsia
(%)
Preeclampsia in a previous pregnancy 138 27 (19.5%)
-Preeclampsia with one or more other risk factors 84 17 (20.2%)
-Preeclampsia and BMI >30kg/m2 21 6 (28.6%)
-Preeclampsia and small for gestational age 20 3 (15.5%)
Chronic hypertension 60 8 (13.3%9
-Chronic hypertension with one or more other risk
factors
55 13 (24.6%)
-Chronic hypertension and BMI >30kg/m2 31 4 (12.9%)
Type 1 diabetes mellitus 11 3 (27.3%)
-Type 1 diabetes mellitus with one or more other risk
factors
7 2 (28.8%)
Age over forty years at entry 102 1 (0.9%)
-Age over forty and BMI >30kg/m2 19 1 (5.3%)
BMI >30kg/m2 227 13 (5.7%)
Sjo¨gren’s syndrome 13 0 (0%)
Systemic lupus erythematosus 4 0 (0%)
https://doi.org/10.1371/journal.pone.0174399.t006
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and SGA pregnancies. If shallow placentation interacts with maternal metabolic disturbances
preeclampsia develops, if metabolic disturbances are absent, SGA develops.
Consistent with earlier studies, we found that chronic hypertension is a stronger predictor
of early-onset and severe preeclampsia [1]. Chronic hypertension may predispose to placental
vascular insufficiency associated with early-onset preeclampsia. Obesity increases the risk of
preeclampsia. In our cohort obese women had increased risk of any, term, and severe pre-
eclampsia. No association with preterm preeclampsia was observed. For example in a popula-
tion based retrospective study with over 854 000 singleton live births the risk ratio for
preeclampsia was 2.9 for all women with BMI over 30 kg/m2 and the risk increased progres-
sively with the increase in BMI [1]. In our cohort, if a woman had other risk factors together
with obesity the risk increased. Obesity together with history of preeclampsia in an earlier
pregnancy increased the risk of intermediate and term preeclampsia, but not early-onset
preeclampsia.
Women in the extremes of fertile age are thought to be at increased risk of developing pre-
eclampsia [1]. This was not seen in our cohort. Women below 20 years and over 40 years of
age did not have increased risk of developing preeclampsia, unless observed together with
other risk factors. Women in extremely advanced maternal age, 45 years or over may be in
greater risk of preeclampsia spectrum complications [30].
Women with connective tissue diseases, systemic lupus erythematous and Sjo¨gren’s syn-
drome, are commonly considered at high risk for developing preeclampsia [31]. However, in
our cohort none included with these risk factors developed preeclampsia. This may be due to
the small sample size. The heterogeneity of these complex diseases may also play a role. It may
be that only some subgroups of women, for example those with lupus anticoagulant or renal
insufficiency, have an increased risk.
Recent advances in the prevention of preeclampsia in high-risk women have emphasized
the identification of these women and the role of individual risk assessment. There is no con-
sensus on the level of risk which would warrant prevention with low dose aspirin and there are
only few recommendations concerning the prevention. These recommendations are based on
the assumption that low dose aspirin should prevent early-onset and severe preeclampsia more
efficiently than late-onset, non-severe disease [12,32]. Society of Obstetric Medicine of Austra-
lia and New Zealand [33] recommends low dose aspirin for women at increased risk. The Soci-
ety of Obstetricians and Gynecologists of Canada [34] recommends low dose aspirin for
women at highest risk, women with a history of early-onset preeclampsia and women with
recurrent preeclampsia. The recommendations by World Health Organization (WHO) [35],
National Institute of Health and Clinical Excellence (NICE) [36], American College of Obste-
tricians and Gynecologists (ACOG) [2] and U.S. Preventive Services Task Force (USPSTF)
[35], provide more detailed guidelines. In July 2016 ACOG released an updated version of rec-
ommendations stating that they support the broader list of risk factors associated with high
risk by USPSTF[37]. Each of the WHO and NICE and USPSTF recommendations identify
previous preeclampsia, diabetes, chronic hypertension, renal disease, and autoimmune disease
as factors associated with risk of pre-eclampsia. USPSTF includes also women who have had
preeclampsia accompanied by adverse outcome. In the NICE guidelines all hypertensive dis-
eases, including pregnancy hypertension in a previous pregnancy, are evaluated as factors with
high risk. In WHO and USPSTF recommendation multiple pregnancy is included as a factor
with high risk. The NICE guidelines and USPSTF determine, as well, moderate risk factors
and recommends to consider low dose aspirin for women with more than one of these moder-
ate risk factors: first pregnancy, age 35 (in USPSTF) or 40 (in NICE) years or older, pregnancy
interval of more than ten years, BMI of 35kg/m2 or more, family history of preeclampsia or
multiple pregnancy. Accumulation of risk factors increasing the risk of preeclampsia is
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corroborated by our cluster analysis. For example age over 40 as a sole factor in a healthy par-
ticipant did not increase the risk of preeclampsia in our cohort, but obese women over forty
years of age had an increased risk of preterm preeclampsia. The USPSTF recommendation
also includes sociodemographic characteristics in the moderate risk factors. The USPSTF rec-
ommendation, unlike others, includes the history of a SGA infant as a moderate risk factor. In
our cohort, history of giving birth to a SGA baby in a previous pregnancy seems to increase
the risk of early, preterm and severe preeclampsia significantly in subsequent pregnancies.
Gestational diabetes in an earlier pregnancy, obesity or advanced age as sole risk factors
does not seem to increase the risk of early-onset or severe preeclampsia. Commercial predic-
tion programs, utilizing placental growth factor, other biomarkers and biophysical measure-
ments are under development. Currently the clinical risk factors are important in estimating
the risk of preeclampsia in early pregnancy and consequently the need for preventive low dose
aspirin. Based on this cluster analysis we would recommend low dose aspirin for those women
who have had preeclampsia or a SGA infant in an earlier pregnancy, women with chronic
hypertension and women with type 1 diabetes mellitus if present as a sole risk factor or
together with other factors. Clustering of risk factors increases the risk significantly.
We conclude that early-onset and severe preeclampsia has different risk profile from the
late-onset preeclampsia. Our analysis indicates exponential increase in the risk of preeclampsia
as the number of risk factors increased.
Supporting information
S1 Table. The risk ratios and 95%CI of the least frequent clusters. The marking C20 etc. is
referring to certain row in the heatmap. If the risk factor is inside brackets, only a portion of
women in the cluster had that risk factor.
(PDF)
S1 Fig. The heatmap with Bonferroni corrections. Results of the cluster analysis. The heat-
map presents the risk factors (columns) in the different clusters on the left side with black
boxes. The rows correspond to the 25 clusters (C1-C25) identified on the basis of the risk fac-
tor profiles, and the sizes of the clusters are shown on the left side of the heat map (n = 226
etc.). The size (i.e. area) of the black box illustrates the proportion of women in the particular
cluster with the risk factor in question. Right side of the heatmap presents the risk ratios of the
outcomes, in this heat map significance is determined using Bonferroni correction over the 25
clusters times 10 outcomes (250 conditions). The colour of the cell represents the estimated
risk ratio of the corresponding outcome in the corresponding cluster, and the colour encoding




We are grateful to the women who participated in the PREDO Project.
Author Contributions
Conceptualization: PMV PM JG AIL KM PT AKP KR EH EK HL.
Data curation: PMV PM JG.
Formal analysis: PM JG PMV.
Cluster analysis to estimate the risk of preeclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0174399 March 28, 2017 12 / 14
Funding acquisition: PMV PM AKP KR EH EK HL.
Investigation: PMV PM JG M-RO PT AKP KR EH EK HL.
Methodology: PM JG.
Project administration: PMV PM AKP KR EH EK HL.
Resources: PMV PM M-RO PT.
Software: PM JG.
Supervision: PM EK HL.
Validation: PM JG.
Visualization: PMV PM JG.
Writing – original draft: PMV PM EK HL.
Writing – review & editing: JG AIL KM M-RO PT AKP KR EH.
References
1. Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-
versus late-onset disease. Am J Obstet Gynecol. 2013; 209: 544.e1–544.e12. http://dx.doi.org/10.
1016/j.ajog.2013.08.019.
2. American College of Obstetricians and Gynecologists. Hypertension in pregnancy Task force recom-
mendations. 2014.
3. Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven’t we cured the disease? J
Reprod Immunol. 2013; 99: 1–9. http://dx.doi.org/10.1016/j.jri.2013.05.003. PMID: 23890710
4. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy.
2003; 22: 143–148. https://doi.org/10.1081/PRG-120021060 PMID: 12908998
5. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclamp-
sia: population based cohort study. BMJ. 2001; 323: 1213–1217. PMID: 11719411
6. Nadeau-Vallee M, Obari D, Palacios J, Brien M, Duval C, Chemtob S, et al. Sterile inflammation and
pregnancy complications: a review. Reproduction. 2016; 152: R277–R292. https://doi.org/10.1530/
REP-16-0453 PMID: 27679863
7. Nelson DB, Ziadie MS, McIntire DD, Rogers BB, Leveno KJ. Placental pathology suggesting that pre-
eclampsia is more than one disease. Am J Obstet Gynecol. 2014; 210: 66.e1–66.e7. http://dx.doi.org/
10.1016/j.ajog.2013.09.010.
8. Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, Powers RW, et al. Redefining pre-
eclampsia using placenta-derived biomarkers. Hypertension. 2013; 61: 932–942. http://dx.doi.org/10.
1161/HYPERTENSIONAHA.111.00250. PMID: 23460278
9. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, et al. Clinical characterization
and outcomes of preeclampsia with normal angiogenic profile. 2013; 32: 189–201.
10. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and
its complications. Cochrane Database Syst Rev. 2007: 004659.
11. Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest JC, et al. Early administration of low-dose
aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am
J Perinatol. 2012; 29: 551–556. http://dx.doi.org/10.1055/s-0032-1310527. PMID: 22495898
12. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi A, et al. Early administration of low-dose
aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis.
2012; 31: 141–146.
13. Villa PM, Kajantie E, Raikkonen K, Pesonen A, Hamalainen E, Vainio M, et al. Aspirin in the prevention
of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analy-
sis of randomised trials. 2013; 120: 64–74.
14. Girchenko P, Hamalainen E, Kajantie E, Pesonen A, Villa P, Laivuori H, et al. Prediction and Prevention
of Preeclampsia and Intrauterine Growth Restriction (PREDO) study. Int J Epidemiol. 2016.
Cluster analysis to estimate the risk of preeclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0174399 March 28, 2017 13 / 14
15. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen A, Taipale P, et al. Vasoactive agents for the
prediction of early- and late-onset preeclampsia in a high-risk cohort. 2013; 13: 110.
16. Knight AK, Craig JM, Theda C, Baekvad-Hansen M, Bybjerg-Grauholm J, Hansen CS, et al. An epige-
netic clock for gestational age at birth based on blood methylation data. Genome Biol. 2016; 17: 206.
https://doi.org/10.1186/s13059-016-1068-z PMID: 27717399
17. Pesonen A, Lahti M, Kuusinen T, Tuovinen S, Villa P, Hamalainen E, et al. Maternal Prenatal Positive
Affect, Depressive and Anxiety Symptoms and Birth Outcomes: The PREDO Study. 2016; 11:
e0150058.
18. [Anonymous]. Report of the National High Blood Pressure Education Program Working Group on High
Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000; 183: S1–S22.
19. Pihkala J, Hakala T, Voutilainen P, Raivio K. [Characteristic of recent fetal growth curves in Finland].
Duodecim. 1989; 105: 1540–1546. PMID: 2680445
20. Bishop CM. Pattern recognition and machine learning. USA: Springer; 2006.
21. Corander J, Marttinen P. Bayesian identification of admixture events using multilocus molecular mark-
ers. Mol Ecol. 2006; 15: 2833–2843. https://doi.org/10.1111/j.1365-294X.2006.02994.x PMID:
16911204
22. Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of preeclampsia-related diagnoses
recorded in a national hospital registry and in a postpartum interview of the women. Am J Epidemiol.
2007; 166: 117–124. https://doi.org/10.1093/aje/kwm139 PMID: 17556761
23. Naimy Z, Grytten J, Monkerud L, Eskild A. The prevalence of pre-eclampsia in migrant relative to native
Norwegian women: a population-based study. BJOG. 2015; 122: 859–865. http://dx.doi.org/10.1111/
1471-0528.12978. PMID: 25040439
24. Klungsoyr K, Harmon QE, Skard LB, Simonsen I, Austvoll ET, Alsaker ER, et al. Validity of pre-eclamp-
sia registration in the medical birth registry of Norway for women participating in the norwegian mother
and child cohort study, 1999–2010. Paediatr Perinat Epidemiol. 2014; 28: 362–371. http://dx.doi.org/10.
1111/ppe.12138. PMID: 25040774
25. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of con-
trolled studies. BMJ. 2005; 330: 565. https://doi.org/10.1136/bmj.38380.674340.E0 PMID: 15743856
26. Mostello D, Kallogjeri D, Tungsiripat R, Leet T,c. Recurrence of preeclampsia: effects of gestational age
at delivery of the first pregnancy, body mass index, paternity, and interval between births. 2008; 199:
55e1–55e7.
27. Wikstrom A,c, Stephansson O,b, Cnattingius S. Previous preeclampsia and risks of adverse outcomes
in subsequent nonpreeclamptic pregnancies. 2011; 204: 148e1–148e6.
28. Bramham K, Briley AL, Seed P, Poston L, Shennan AH, Chappell LC. Adverse maternal and perinatal
outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol. 2011; 204:
512.e1–512.e9. http://dx.doi.org/10.1016/j.ajog.2011.02.014.
29. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restric-
tion and preeclampsia. Am J Obstet Gynecol. 2006; 195: 40–49. https://doi.org/10.1016/j.ajog.2005.07.
049 PMID: 16813742
30. Yogev Yariv, Nir M, Ron B, Kinneret T, Gadi B, et al. Pregnancy outcome at extremely advanced mater-
nal age. 2010; 203: 558e1–558e7.
31. Ostensen M, Clowse M. Pathogenesis of pregnancy complications in systemic lupus erythematosus.
Curr Opin Rheumatol. 2013; 25: 591–596. http://dx.doi.org/10.1097/BOR.0b013e328363ebf7. PMID:
23917157
32. Roberge S, Giguere Y, Villa P, Nicolaides K, Vainio M, Forest J, et al. Early administration of low-dose
aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am
J Perinatol. 2012; 29: 551–556. https://doi.org/10.1055/s-0032-1310527 PMID: 22495898
33. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, et al. The SOMANZ Guidelines for
the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol.
34. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, SOGC Hypertension Guideline Committee.
Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive sum-
mary. 2014; 36: 575–576.
35. WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia.2011.
36. National Institute of Health and Excellence. NICE clinical guideline 107 National Institute for Health and
Excellence: Hypertension in pregnancy. The management of hypertensive disorders during pregnancy.
37. American College of Obstetricians and Gynecologists. Practise Advisory on Low-Dose Aspirin and Pre-
vention of Preeclampsia: Updated Recommendatios. 2016.
Cluster analysis to estimate the risk of preeclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0174399 March 28, 2017 14 / 14
